Insmed | INSM - Cash And Equivalent


Insmed reported $510.44M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
Cytokinetics USD 225.47M 150.53M Sep/2025
DBV Technologies USD 69.84M 33.37M Sep/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
Heron Therapeutics USD 43.07M 26.55M Sep/2025
Insmed USD 510.44M 175.68M Dec/2025
Novartis USD 9.56B 2.9B Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Vertex Pharmaceuticals USD 6.61B 321.1M Dec/2025